Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × merestinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Neoplasms 2 Neoplasm Metastasis 2 Breast Neoplasms 2 Pancreatic Neoplasms 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Gallbladder Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

pembrolizumab 268 Nivolumab 241 Ipilimumab 221 aldesleukin 126 Cyclophosphamide 126 Interleukin-2 93 trametinib 76 dabrafenib 68 Dacarbazine 68 Temozolomide 66 fludarabine 64 Vemurafenib 64 fludarabine phosphate 56 Biopsy 45 Radiosurgery 43 sargramostim 40 Bevacizumab 40 binimetinib 39 incomplete Freund's adjuvant 37 Paclitaxel 35 atezolizumab 34 Radiotherapy 34 Cisplatin 34 Blood Specimen Collection 33 encorafenib 32 Magnetic Resonance Spectroscopy 32 cobimetinib 31 Specimen Handling 31 Introns 31 Carboplatin 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02791334 2024-09-27

PACT

Eli Lilly and Company

Phase 1 Completed

BreastDermatologicGastrointestinal

Breast Neoplasms, Melanoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡